Submitted:
17 April 2023
Posted:
18 April 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Tool
2.2. Statistical Analysis
3. Results
3.1. Sociodemographic Characteristics
3.2. Pharmacist Experience with Loperamide Use and Abuse
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Tommasello, A.C. Substance abuse and pharmacy practice: what the community pharmacist needs to know about drug abuse and dependence. Harm Reduct J 2004, 1, 3. [Google Scholar] [CrossRef]
- Algarni, M.; Hadi, M.A.; Yahyouche, A.; Mahmood, S.; Jalal, Z. A mixed-methods systematic review of the prevalence, reasons, associated harms and risk-reduction interventions of over-the-counter (OTC) medicines misuse, abuse and dependence in adults. J of Pharm Policy and Pract 2021, 14, 76. [Google Scholar] [CrossRef] [PubMed]
- Powell, J.W.; Presnell, S.E. Loperamide as a Potential Drug of Abuse and Misuse: Fatal Overdoses at the Medical University of South Carolina. J Forensic Sci 2019, 64, 1726–1730. [Google Scholar] [CrossRef]
- Borron, S.W.; Watts, S.H.; Tull, J.; Baeza, S.; Diebold, S.; Barrow, A. Intentional Misuse and Abuse of Loperamide: A New Look at a Drug with “Low Abuse Potential”. The Journal of Emergency Medicine 2017, 53, 73–84. [Google Scholar] [CrossRef]
- Lasoff, D.R.; Koh, C.H.; Corbett, B.; Minns, A.B.; Cantrell, F.L. Loperamide Trends in Abuse and Misuse Over 13 Years: 2002-2015. Pharmacotherapy 2017, 37, 249–253. [Google Scholar] [CrossRef] [PubMed]
- Vakkalanka, J.P.; Charlton, N.P.; Holstege, C.P. Epidemiologic Trends in Loperamide Abuse and Misuse. Annals of Emergency Medicine 2017, 69, 73–78. [Google Scholar] [CrossRef] [PubMed]
- Lee, V.R.; Vera, A.; Alexander, A.; Ruck, B.; Nelson, L.S.; Wax, P.; Campleman, S.; Brent, J.; Calello, D.P. Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk. Clinical Toxicology 2019, 57, 175–180. [Google Scholar] [CrossRef]
- Schifano, F.; Chiappini, S. Is there such a thing as a'lope'dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. PLoS One 2018, 13, e0204443. [Google Scholar] [CrossRef]
- Antoniou, T.; Juurlink, D.N. Loperamide abuse. Canadian Medical Association Journal 2017, 189, E803–E803. [Google Scholar] [CrossRef]
- Whittaker, G.; Newman, J. Loperamide: an emerging drug of abuse and cause of prolonged QTc. Clin Med 2021, 21, 150–152. [Google Scholar] [CrossRef]
- Sun, S.; White, B. Pharmacist and Prescriber Responsibilities for Avoiding Prescription Drug Misuse. AMA Journal of Ethics 2021, 23, 471–479. [Google Scholar]
- Feldman, R.; Everton, E. National assessment of pharmacist awareness of loperamide abuse and ability to restrict sale if abuse is suspected. Journal of the American Pharmacists Association 2020, 60, 868–873. [Google Scholar] [CrossRef] [PubMed]
- Mobrad, A.M.; Alghadeer, S.; Syed, W.; Al-Arifi, M.N.; Azher, A.; Almetawazi, M.S.; Babelghaith, S.D. Knowledge, Attitudes, and Beliefs Regarding Drug Abuse and Misuse among Community Pharmacists in Saudi Arabia. IJERPH 2020, 17, 1334. [Google Scholar] [CrossRef]
- Barakat, M.; Al-Qudah, R.a.; Akour, A.; Al-Qudah, N.; Dallal Bashi, Y.H. Unforeseen uses of oral contraceptive pills: Exploratory study in Jordanian community pharmacies. PLOS ONE 2020, 15, e0244373. [Google Scholar] [CrossRef]
- Barakat, M.M.; Al-Qudah, R.a.A.; Akour, A.; Abu-Asal, M.; Thiab, S.; Dallal Bashi, Y.H. The Use/Abuse of Oral Contraceptive Pills Among Males: A Mixed-Method Explanatory Sequential Study Over Jordanian Community Pharmacists; Addiction Medicine: 2021/03/12/ 2021.
- Albsoul-Younes, A.; Wazaify, M.; Yousef, A.-M.; Tahaineh, L. Abuse and Misuse of Prescription and Nonprescription Drugs Sold in Community Pharmacies in Jordan. Substance Use & Misuse 2010, 45, 1319–1329. [Google Scholar] [CrossRef]
- Al-Husseini, A.; Abu-Farha, R.; Wazaify, M.; Van Hout, M.C. Pregabalin dispensing patterns in Amman-Jordan: An observational study from community pharmacies. Saudi pharmaceutical journal 2018, 26, 306–310. [Google Scholar] [CrossRef] [PubMed]
- Tabachnick, B.G.; Fidell, L.S.; Ullman, J.B. Using multivariate statistics; Pearson Boston, MA: 2007; Volume 5.
- Chowdhury, M.Z.I.; Turin, T.C. Variable selection strategies and its importance in clinical prediction modelling. Family medicine community health 2020, 8.
- Wazaify, M.; Abood, E.; Tahaineh, L.; Albsoul-Younes, A. Jordanian community pharmacists’ experience regarding prescription and nonprescription drug abuse and misuse in Jordan–An update. Journal of Substance Use 2017, 22, 463–468. [Google Scholar] [CrossRef]
- Webb, N.E.; Wood, D.M.; Black, J.C.; Amioka, E.; Dart, R.C.; Dargan, P.I. Non-medical use of loperamide in the UK and the USA. QJM: An International Journal of Medicine 2020, 113, 25–30. [Google Scholar] [CrossRef]
- (UNDC), U.N.o.o.d.a.c. World drug report, EXECUTIVE SUMMARY POLICY IMPLICATIONS; 2022.
- Chung, C.-H.; Lin, I.-J.; Huang, Y.-C.; Sun, C.-A.; Chien, W.-C.; Tzeng, N.-S. The association between abused adults and substance abuse in Taiwan, 2000–2015. BMC psychiatry 2023, 23, 1–7. [Google Scholar] [CrossRef]
- Daniulaityte, R.; Carlson, R.; Falck, R.; Cameron, D.; Perera, S.; Chen, L.; Sheth, A. “I just wanted to tell you that loperamide WILL WORK”: a web-based study of extra-medical use of loperamide. Drug alcohol dependence 2013, 130, 241–244. [Google Scholar] [CrossRef]
- Lee, V.R.; Vera, A.; Alexander, A.; Ruck, B.; Nelson, L.S.; Wax, P.; Campleman, S.; Brent, J.; Calello, D. Loperamide misuse to avoid opioid withdrawal and to achieve a euphoric effect: high doses and high risk. Clinical Toxicology 2019, 57, 175–180. [Google Scholar] [CrossRef] [PubMed]
- Major, C.; Vincze, Z. Consumer habits and interests regarding non-prescription medications in Hungary. Family Practice 2010, 27, 333–338. [Google Scholar] [CrossRef]
- Sansgiry, S.S.; Bhansali, A.H.; Bapat, S.S.; Xu, Q. Abuse of over-the-counter medicines: a pharmacist’s perspective. Integrated Pharmacy Research Practice 2016, 1–6. [Google Scholar] [CrossRef]
- Hughes, C.M. Monitoring self-medication. 2003, 2, 1–5.
- Paxton, R.; Chapple, P. Misuse of over-the-counter medicines: a survey in one English county. Pharmaceutical Journal 1996, 256, 313–315. [Google Scholar]
- Bates, D.; Deering, M.J.; Leavitt, M. E-pharmacy: improving patient care and managing risk. Journal of the American Pharmaceutical Association 2002, 42, S20–S21. [Google Scholar]
- Shastay, A. Dangerous Abuse of a 40-Year-Old Over-the-Counter Medication, Loperamide. Home Healthcare Now 2020, 38, 167–168. [Google Scholar] [CrossRef] [PubMed]
- Sapra, A.; Bhandari, P.; Gupta, S.; Kraleti, S.; Bahuva, R. A Rising Concern of Loperamide Abuse: A Case Report on Resulting Cardiac Complications. Cureus 2019, 11. [Google Scholar] [CrossRef] [PubMed]
- Chisholm-Burns, M.A.; Spivey, C.A.; Sherwin, E.; Wheeler, J.; Hohmeier, K. The opioid crisis: origins, trends, policies, and the roles of pharmacists. American journal of health-system pharmacy 2019, 76, 424–435. [Google Scholar] [CrossRef] [PubMed]



| Variables | n (%) |
| Gender | |
| o Female | 135(54.0) |
| o Male | 115 (46.0) |
| Age | |
| o 20-30 | 75 (30.0) |
| o 31-40 | 75 (30.0) |
| o 41-50 | 70 (28.0) |
| o >50 | 30 (12.0) |
| Educational level | |
| o Diploma | 31 (12.4) |
| o Bachelor's degree | 207 (82.8) |
| o Postgraduate degree | 12 (4.8) |
| Location of the pharmacy | |
| o North Jordan | 35 (14.0) |
| o Middle of Jordan | 186 (74.4) |
| o South Jordan | 29 (11.6) |
| Pharmacy location is in the | |
| o Main Road | 165 (66.0) |
| o Side Road | 79 (31.6) |
| o Mall | 6 (2.4) |
| Type of the pharmacy | |
| o Chain pharmacy | 90 (36.0) |
| o Community pharmacy | 160 (64.0) |
| Pharmacists working in a pharmacy have a monthly incentive system based on the quantity of medicines sold per month | |
| o No | 112 (44.8) |
| o Yes | 138 (55.2) |
| The main employment role in the pharmacy | |
| o Principal pharmacist | 221 (88.4) |
| o Pharmacist assistant | 29 (11.6) |
| Years of experience in the pharmaceutical field | |
| o < 5 | 61 (24.4) |
| o 5-10 | 71 (28.4) |
| o >10 | 118 (47.2) |
| Working shift at the pharmacy | |
| o First Shift (A, 8 AM-4 PM) | 64 (25.6) |
| o Second Shift (B, 4-12 AM) | 21 (8.4) |
| o Third Sift (C, 12 AM-8 AM) | 70 (28.0) |
| o Variable periods | 95 (38.0) |
| The general socioeconomic status of patients who visit the pharmacy | |
| o Low | 29 (11.6) |
| o Low to middle | 110 (44.0) |
| o Middle | 79 (31.6) |
| o High | 32 (12.8) |
| Variables | n (%) |
| During the past six months, have you had cases of suspected Loperamide abuse | |
| o Yes | 83 (33.2) |
| o No | 156 (62.4) |
| o Not sure | 11 (4.4) |
| The products that you suspect that there is an increase in its abuse in Jordan (More than one answer was allowed) * | |
| o Diapen Caps | 47 (56.6) |
| o Imodium Caps | 69 (83.1) |
| o Imodium Instant ODT | 60 (72.3) |
| o Imotril Cap | 53 (63.9) |
| o Loperium Tab | 69 (83.1) |
| o Vacontil Tab | 56 (67.5) |
| o Others | 2 (2.4) |
| In general, the socioeconomic status of the suspected Loperamide abusers (for any of the products mentioned above) * | |
| o Low | 22 (26.5) |
| o Low-middle | 58 (69.9) |
| o Middle | 3 (3.6) |
| The gender category of the suspected Loperamide abusers* | |
| o Females | 4 (4.8) |
| o Males | 50 (60.2) |
| o Both | 29 (34.9) |
| The age group of of the suspected Loperamide abusers* | |
| o 20-30 | 48 (57.8) |
| o 31-40 | 25 (30.1) |
| o Variable | 10 (12.1) |
| Type of customers who request Loperamide for suspected abuse purposes* | |
| o Strangers | 14 (16.9) |
| o Regular customers | 1 (1.2) |
| o Both | 68 (81.9) |
| From your experience, the rate of abuse of Loperamide is* | |
| o Decreasing | 3 (3.6) |
| o No changes | 9 (10.8) |
| o Increasing | 71 (85.5) |
| What was the largest quantity (packs) of this product I have ordered for a single patient? | |
| Mean (SD) | 33.2 (14.9) |
| Pharmacists could recognize suspected Loperamide abusers by (more than one answer was allowed)* | |
| o They ask directly and acknowledge their needs | 57 (68.7) |
| o Unusual appearance (extreme lack of concern for appearance or dress) | 62 (74.7) |
| o Mood disturbances, inability to control impulses and thought disturbances may appear | 74 (89.2) |
| o Exaggerates medical problems and/or mimics symptoms to get medication | 75 (89.2) |
| o Often orders medication specifically and refuses alternatives to other antidiarrheal drugs | 44 (53.0) |
| o Reluctance or unwillingness to provide reference information | 60 (72.3) |
| o May show extraordinary knowledge of antidiarrheals or controlled drugs | 43 (51.8) |
| o None, unrecognizable | 2 (2.4) |
| *Percentages were calculated based on the number of the pharmacist who reported Loperamide abuse (n=83) | |
| Predictor | P-value | Odds Ratio | 95% CI | |
|---|---|---|---|---|
| Lower | Upper | |||
| Gender | ||||
| o Female | Ref | |||
| o Male | 0.001 | 1.269 | 0.122 | 1.590 |
| Educational level | ||||
| o Diploma | Ref | |||
| o University degree | 0.696 | 1.642 | 0.136 | 19.791 |
| Location of the pharmacy | ||||
| o Non-center of Jordan | Ref | |||
| o Center of Jordan (including the capital) | 0.005 | 21.238 | 2.457 | 183.588 |
| Pharmacy location is in the | ||||
| o Main Road | Ref | |||
| o Side Road | 0.069 | 22.193 | 0.790 | 623.318 |
| Years of experience in the pharmaceutical field | ||||
| o <10 | Ref | |||
| o >10 | 0.590 | 0.7299 | 0.232 | 2.292 |
| Working shift at the pharmacy | ||||
| o Shift A/B | Ref | |||
| o Third Sift (C, 12-8 AM) | 0.002 | 1.288 | 0.129 | 2.0842 |
| The general socioeconomic status of patients who visit the pharmacy | ||||
| o Middle/High | Ref | |||
| o Low/Low-Middle | 0.062 | 0.230 | 0.049 | 1.079 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).